Differential recovery of prostacyclin synthesis in cultured vascular endothelial vs. smooth muscle cells after inactivation of cyclooxygenase with aspirin.
Conflicting findings from clinical trials on the use of aspirin in preventing myocardial infarction emphasize the importance of understanding the effects of aspirin on vascular cells. Cultured vascular endothelial cells and smooth muscle cells of human, rat and bovine origin synthesized prostacyclin, a key component in vascular homeostasis, when superfused with 14C arachidonic acid. Prostacyclin synthesis was inactivated following brief treatment with aspirin, which irreversibly acetylates cyclooxygenase. Marked differences were observed between endothelial and smooth muscle cells in the recovery of cyclooxygenase after aspirin treatment. Smooth muscle cells recovered within 3 hours by a process that required serum factors replaceable by epidermal growth factor (EGF) and TGF-beta. Recovery in both smooth muscle and endothelial cells was blocked by cycloheximide but not by actinomycin-D. Endothelial cell recovery occurred much more slowly, requiring up to 24 hours and was not dependent on serum factors or EGF. Furthermore, it was suppressed by growth inducing agents such as endothelial cell growth factor (ECGF) and was enhanced by conditions favoring growth arrest and cellular differentiation. Regulation of expression and recovery of cyclooxygenase following inactivation by aspirin thus differs considerably in the endothelial and smooth muscle compartments of the vasculature.
Hla
T T
TT
Department of Biochemistry, George Washington University School of Medicine, Washington, D.C. 20037.
Bailey
J M
JM
D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D002417:Cattle; D002478:Cells, Cultured; D002855:Chromatography, Thin Layer; D003513:Cycloheximide / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors; D003609:Dactinomycin / Q000494:pharmacology; D016228:Endothelial Growth Factors; D004730:Endothelium, Vascular / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000502:physiology; D011464:Epoprostenol / Q000096:biosynthesis*; D005786:Gene Expression Regulation; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D051381:Rats; D013936:Thymidine / Q000493:pharmacokinetics
D016861:Cyclooxygenase Inhibitors; D016228:Endothelial Growth Factors; D006133:Growth Substances; D003609:Dactinomycin; D004815:Epidermal Growth Factor; D003513:Cycloheximide; D011464:Epoprostenol; D001241:Aspirin; D013936:Thymidine